ASM is a therapeutic target in dermatomyositis by regulating the differentiation of naive CD4 + T cells into Th17 and Treg subsets.

Skelet Muscle · 2024 · PMC11256435 · PMID 39026344

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Furthermore, we analyzed the Treg ratio of CD25 + Foxp3 + versus CD25-Foxp3 + in EAM models, the data indicated a decreasing trend in the Treg ratio after knocking out SMPD1 or inhibiting ASM activity with amitriptyline (Fig. 4 G-H).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.